Diploma (LON:DPLM) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Diploma (LON:DPLM) had its price objective hoisted by investment analysts at Royal Bank Of Canada from GBX 6,200 to GBX 6,600 in a research report issued on Thursday, MarketBeat Ratings reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target points to a potential upside of 15.53% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. Shore Capital Group reaffirmed a “hold” rating on shares of Diploma in a research note on Wednesday. Peel Hunt reissued a “buy” rating and issued a GBX 6,150 target price on shares of Diploma in a research note on Friday, December 19th. Stifel Nicolaus boosted their price target on Diploma from GBX 6,200 to GBX 6,800 and gave the company a “buy” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft increased their price objective on Diploma from GBX 6,000 to GBX 6,200 and gave the stock a “buy” rating in a report on Wednesday, January 14th. Finally, Berenberg Bank reiterated a “buy” rating and issued a GBX 6,350 price objective on shares of Diploma in a research report on Wednesday, November 19th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of GBX 6,023.75.

Diploma Trading Down 1.8%

Shares of DPLM opened at GBX 5,712.95 on Thursday. The stock has a market capitalization of £7.66 billion, a P/E ratio of 41.61, a PEG ratio of 2.82 and a beta of 1.03. Diploma has a twelve month low of GBX 3,532 and a twelve month high of GBX 6,019.52. The company has a quick ratio of 0.80, a current ratio of 2.04 and a debt-to-equity ratio of 46.97. The firm has a fifty day simple moving average of GBX 5,457.51 and a two-hundred day simple moving average of GBX 5,425.55.

Insider Activity

In related news, insider Katie Bickerstaffe bought 352 shares of the business’s stock in a transaction dated Wednesday, January 14th. The shares were purchased at an average price of GBX 5,645 per share, with a total value of £19,870.40. Also, insider Ian El-Mokadem purchased 500 shares of Diploma stock in a transaction that occurred on Wednesday, January 14th. The shares were bought at an average price of GBX 5,615 per share, for a total transaction of £28,075. Insiders own 1.14% of the company’s stock.

Key Stories Impacting Diploma

Here are the key news stories impacting Diploma this week:

• Positive Sentiment: Surprise profit upgrade forced a re‑rating of consensus and sparked a ~17% share jump as investors digested stronger-than-expected guidance. Diploma shares surge 17% as surprise profit upgrade exposes the bearish consensus
• Positive Sentiment: Guidance upgrade lifted Diploma’s earnings forecasts (~15%) and prompted price-target increases (headline 6,600p), reinforcing the bullish re-rate. Diploma price target lifted to 6,600p after guidance upgrade drives 15% earnings forecast rise
• Positive Sentiment: Berenberg raised its price target sharply to GBX 7,500 and moved to a “buy” rating, signaling confidence in the upgraded outlook. Broker ratings
• Positive Sentiment: Stifel increased its target to GBX 6,800 and upgraded to “buy”, adding to the cluster of upward revisions from brokers. Broker ratings
• Positive Sentiment: Deutsche Bank raised its target to GBX 6,400 and now carries a “buy” stance, supporting the upward momentum. Broker ratings
• Positive Sentiment: Royal Bank of Canada lifted its target to GBX 6,600 and set an “outperform” rating — another well‑known house backing the upgraded story. RBC note
• Negative Sentiment: Shore Capital reaffirmed a “hold” rating on 20 March, which may have damped some of the rally and encouraged profit‑taking after the sharp run. Shore Capital Group Reaffirms Hold Rating for Diploma

Diploma Company Profile

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.